Advertisement

Newer Technologies in Ocular Oncology

  • Puneet JainEmail author
  • Paul T. Finger
Chapter
Part of the Current Practices in Ophthalmology book series (CUPROP)

Abstract

The emergence of technology has transformed ophthalmic oncology from a surgical specialty to one that involves both medical and radiation oncology. With that transition ocular oncologists began to use chemotherapeutic agents and specialized radiation techniques. The first use of radiation focused on eye and vision-sparing external beam for retinoblastoma and implant “plaque” brachytherapy for uveal melanoma. However, the evolution did not stop there. Laser photocoagulation was found useful in the treatment of radiation vasculopathy, cryotherapy for conjunctival tumors, topical chemotherapy, and more. Herein, we discuss the most recent additions to the armamentarium used by ocular oncologists to save eyes, vision, and life.

References

  1. 1.
    Askew DA, Mickan SM, Soyer HP, Wilkinson D. Effectiveness of 5-fluorouracil treatment for actinic keratosis–a systematic review of randomized controlled trials. Int J Dermatol. 2009;48(5):453–63.PubMedCrossRefGoogle Scholar
  2. 2.
    Couch SM, Custer PL. Topical 5-fluorouracil for the treatment of periocular actinic keratosis and low-grade squamous malignancy. Ophthalmic Plast Reconstr Surg. 2012;28(3):181–3.PubMedCrossRefGoogle Scholar
  3. 3.
    Ross AH, Kennedy CT, Collins C, Harrad RA. The use of imiquimod in the treatment of periocular tumours. Orbit. 2010;29(2):83–7.PubMedCrossRefGoogle Scholar
  4. 4.
    Naik MP, Mehta A, Abrol S, Kumar S, Gupta VS. Topical 5% 5-fluorouracil in the treatment of multifocal basal cell carcinoma of the face: a novel chemotherapeutic approach. Orbit. 2016;35(6):352–4.PubMedCrossRefGoogle Scholar
  5. 5.
    de Macedo EM, Carneiro RC, de Lima PP, Silva BG, Matayoshi S. Imiquimod cream efficacy in the treatment of periocular nodular basal cell carcinoma: a non-randomized trial. BMC Ophthalmol. 2015;15:35.PubMedPubMedCentralCrossRefGoogle Scholar
  6. 6.
    Shi Y, Jia R, Fan X. Ocular basal cell carcinoma: a brief literature review of clinical diagnosis and treatment. Onco Targets Ther. 2017;10:2483–9.PubMedPubMedCentralCrossRefGoogle Scholar
  7. 7.
    Karabulut GO, Kaynak P, Ozturker C, Fazil K, Ocak OB, Taskapılı M. Imiquimod 5% cream for the treatment of large nodular basal cell carcinoma at the medial canthal area. Indian J Ophthalmol. 2017;65(1):48–51.PubMedPubMedCentralCrossRefGoogle Scholar
  8. 8.
    Garcia-Martin E, Gil-Arribas LM, Idoipe M, Alfaro J, Pueyo V, Pablo LE, et al. Comparison of imiquimod 5% cream versus radiotherapy as treatment for eyelid basal cell carcinoma. Br J Ophthalmol. 2011;95(10):1393–6.PubMedCrossRefGoogle Scholar
  9. 9.
    Blasi MA, Maceroni M, Sammarco MG, Pagliara MM. Mitomycin C or interferon as adjuvant therapy to surgery for ocular surface squamous neoplasia: comparative study. Eur J Ophthalmol. 2018;28(2):204–9.PubMedCrossRefGoogle Scholar
  10. 10.
    Rudkin AK, Muecke JS. Adjuvant 5-fluorouracil in the treatment of localised ocular surface squamous neoplasia. Br J Ophthalmol. 2011;95(7):947–50.PubMedCrossRefGoogle Scholar
  11. 11.
    Chaugule SS, Park J, Finger PT. Topical chemotherapy for giant ocular surface squamous neoplasia of the conjunctiva and cornea: is surgery necessary? Indian J Ophthalmol. 2018;66(1):55–60.PubMedPubMedCentralCrossRefGoogle Scholar
  12. 12.
    Joag MG, Sise A, Murillo JC, Sayed-Ahmed IO, Wong JR, Mercado C, et al. Topical 5-fluorouracil 1% as primary treatment for ocular surface squamous neoplasia. Ophthalmology. 2016;123(7):1442–8.PubMedPubMedCentralCrossRefGoogle Scholar
  13. 13.
    Parrozzani R, Frizziero L, Trainiti S, Testi I, Miglionico G, Pilotto E, et al. Topical 1% 5-fluoruracil as a sole treatment of corneoconjunctival ocular surface squamous neoplasia: long-term study. Br J Ophthalmol. 2017;101(8):1094–9.PubMedCrossRefGoogle Scholar
  14. 14.
    Frucht-Pery J, Sugar J, Baum J, Sutphin JE, Pe’er J, Savir H, et al. Mitomycin C treatment for conjunctival-corneal intraepithelial neoplasia: a multicenter experience. Ophthalmology. 1997;104(12):2085–93.PubMedCrossRefGoogle Scholar
  15. 15.
    Ballalai PL, Erwenne CM, Martins MC, Lowen MS, Barros JN, et al. Long-term results of topical mitomycin C 0.02% for primary and recurrent conjunctival-corneal intraepithelial neoplasia. Ophthalmic Plast Reconstr Surg. 2009;25(4):296–9.PubMedCrossRefGoogle Scholar
  16. 16.
    Gupta A, Muecke J. Treatment of ocular surface squamous neoplasia with Mitomycin C. Br J Ophthalmol. 2010;94(5):555–8.PubMedCrossRefGoogle Scholar
  17. 17.
    Finger PT, Milner MS, McCormick SA. Topical chemotherapy for conjunctival melanoma. Br J Ophthalmol. 1993;77(10):751–3.PubMedPubMedCentralCrossRefGoogle Scholar
  18. 18.
    Finger PT, Czechonska G, Liorikos S. Topical mitomycin-C chemotherapy for conjunctival melanoma and PAM with atypia. Br J Ophthalmol. 1998;82(5):476–9.PubMedPubMedCentralCrossRefGoogle Scholar
  19. 19.
    Kurli M, Finger PT. Topical Mitomycin chemotherapy for conjunctival malignant melanoma and primary acquired melanosis with atypia: 12 years’ experience. Graefes Arch Clin Exp Ophthalmol. 2005;243(11):1108–14.PubMedCrossRefGoogle Scholar
  20. 20.
    Finger PT, Sedeek RW, Chin KJ. Topical interferon Alfa in the treatment of conjunctival melanoma and primary acquired melanosis complex. Am J Ophthalmol. 2008;145(1):124–9.PubMedCrossRefGoogle Scholar
  21. 21.
    Klauber S, Jensen PK, Prause JU, Kessing SV. Surgical treatment of iris and ciliary body melanoma: follow-up of a 25-year series of patients. Acta Ophthalmol. 2012;90(2):122–6.PubMedCrossRefGoogle Scholar
  22. 22.
    Shields CL, Manquez ME, Ehya H, Mashayekhi A, Danzig CJ, Shields JA. Fine-needle aspiration biopsy of iris tumors in 100 consecutive cases: technique and complications. Ophthalmology. 2006;113(11):2080–6.PubMedCrossRefGoogle Scholar
  23. 23.
    Finger PT, Latkany P, Kurli M, Iacob C. The finger iridectomy technique: small incision biopsy of anterior segment tumors. Br J Ophthalmol. 2005;89(8):946–9.PubMedPubMedCentralCrossRefGoogle Scholar
  24. 24.
    Petousis V, Finger PT, Milman T. Anterior segment tumor biopsy using an aspiration cutter technique: clinical experience. Am J Ophthalmol. 2011;152(5):771–5.PubMedCrossRefGoogle Scholar
  25. 25.
    Finger PT, Milman T. Microincision, aspiration cutter-assisted multifocal iris biopsy for melanoma. Eur J Ophthalmol. 2017;27(1):62–6.PubMedCrossRefGoogle Scholar
  26. 26.
    Finger PT. Radiation therapy for choroidal melanoma. Surv Ophthalmol. 1997;42(3):215–32.PubMedCrossRefGoogle Scholar
  27. 27.
    Petousis V, Chin KJ, Finger PT. Palladium-103 plaque radiation therapy of the anterior segment of the eye: treatment for diffuse iris melanoma. Graefes Arch Clin Exp Ophthalmol. 2011;249(6):937–40.PubMedCrossRefGoogle Scholar
  28. 28.
    Finger PT. Finger’s amniotic membrane buffer technique protecting the cornea during radiation plaque therapy. Arch Ophthalmol. 2008;126(4):531–4.PubMedCrossRefGoogle Scholar
  29. 29.
    Marigo FA, Finger PT. Anterior segment tumors: current concepts and innovations. Surv Ophthalmol. 2003;48(6):569–93.PubMedCrossRefGoogle Scholar
  30. 30.
    Kivelä T. Alive with good vision: the ultimate goal in managing retinoblastoma. Clin Exp Ophthalmol. 2012;40(7):655–6.PubMedCrossRefGoogle Scholar
  31. 31.
    Karcioglu ZA, Gordon RA, Karcioglu GL. Tumor seeding in ocular fine needle aspiration biopsy. Ophthalmology. 1985;92(12):1763–7.CrossRefGoogle Scholar
  32. 32.
    Manjandavida FP, Shields CL. The role of intravitreal chemotherapy for retinoblastoma. Indian J Ophthalmol. 2015;63(2):141–5.PubMedPubMedCentralCrossRefGoogle Scholar
  33. 33.
    Munier FL, Gaillard MC, Balmer A, Soliman S, Podilsky G, Moulin AP, et al. Intravitreal chemotherapy for vitreous disease in retinoblastoma revisited: from prohibition to conditional indications. Br J Ophthalmol. 2012;96(8):1078–83.PubMedCrossRefGoogle Scholar
  34. 34.
    Smith SJ, Smith BD, Mohney BG. Ocular side effects following intravitreal injection therapy for retinoblastoma: a systematic review. Br J Ophthalmol. 2014;98(3):292–7.PubMedCrossRefGoogle Scholar
  35. 35.
    Reese AB, Hyman GA, Merriam GR Jr, Forrest AW, Kligerman MM. Treatment of retinoblastoma by radiation and triethylenemelamine. AMA Arch Ophthalmol. 1954;53(4):505–13.PubMedCrossRefGoogle Scholar
  36. 36.
    Kiribuchi M, Hasegawa H. Retrograde infusion of anti-cancer drugs to the ophthalmic artery for intra ocular malignant tumors. Iryo. 1968;22(7):772–6.PubMedGoogle Scholar
  37. 37.
    Abramson DH, Shields CL, Jabbour P, Teixeira LF, Fonseca J, Marques M, et al. Metastatic deaths in retinoblastoma patients treated with intraarterial chemotherapy (ophthalmic artery chemosurgery) worldwide. Int J Retina Vitreous. 2017;3:40.PubMedPubMedCentralCrossRefGoogle Scholar
  38. 38.
    Yousef YA, Soliman SE, Astudillo PP, Durairaj P, Dimaras H, Chan HS, et al. Intra-arterial chemotherapy for retinoblastoma a systematic review. JAMA Ophthalmol. 2016;134(5):584–91.PubMedCrossRefGoogle Scholar
  39. 39.
    Meldrum ML, Tse DT, Benedetto P. Neoadjuvant intracarotid chemotherapy for treatment of advanced adenocystic carcinoma of the lacrimal gland. Arch Ophthalmol. 1998;116(3):315–21.PubMedCrossRefGoogle Scholar
  40. 40.
    Tse DT, Kossler AL, Feuer WJ, Benedetto PW. Long-term outcomes of neoadjuvant intra-arterial cytoreductive chemotherapy for lacrimal gland adenoid cystic carcinoma. Ophthalmology. 2013;120(7):1313–23.PubMedPubMedCentralCrossRefGoogle Scholar
  41. 41.
    Packer S, Rotman M. Radiotherapy of choroidal melanoma with iodine-125. Ophthalmology. 1980;87(6):582–90.PubMedCrossRefGoogle Scholar
  42. 42.
    The Collaborative Ocular Melanoma Study Group. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma, III: initial mortality findings COMS Report No. 18. Arch Ophthalmol. 2001;119(7):969–82.CrossRefGoogle Scholar
  43. 43.
    Lommatzsch PK. Results after beta-irradiation (106Ru/106Rh) of choroidal melanomas. Twenty years’ experience. Am J Clin Oncol. 1987;10(2):146–51.PubMedCrossRefGoogle Scholar
  44. 44.
    Finger PT, Chin KJ, Duvall G, Palladium-103 for Choroidal Melanoma Study Group. Palladium-103 ophthalmic plaque radiation therapy for choroidal melanoma: 400 treated patients. Ophthalmology. 2009;116(4):790–6.CrossRefGoogle Scholar
  45. 45.
    Finger PT. Finger’s “slotted” eye plaque for radiation therapy: treatment of juxtapapillary and circumpapillary intraocular tumors. Br J Ophthalmol. 2007;91(7):891–4.PubMedPubMedCentralCrossRefGoogle Scholar
  46. 46.
    Finger PT, Chin KJ, Tena LB. A five-year study of slotted eye plaque radiation therapy for choroidal melanoma: near, touching, or surrounding the optic nerve. Ophthalmology. 2012;119(2):415–22.PubMedCrossRefGoogle Scholar
  47. 47.
    Maheshwari A, Finger PT. A 12-year study of slotted palladium-103 plaque radiation therapy for choroidal melanoma: near, touching, or surrounding the optic nerve. Am J Ophthalmol. 2018;188:60–9.PubMedCrossRefGoogle Scholar
  48. 48.
    The American Brachytherapy Society - Ophthalmic Oncology Task Force. The American Brachytherapy Society consensus guidelines for plaque brachytherapy of uveal melanoma and retinoblastoma. Brachytherapy. 2014;13(1):1–14.CrossRefGoogle Scholar
  49. 49.
    Finger PT. Radiation therapy for orbital tumors: concepts, current use and ophthalmic radiation side effects. Surv Ophthalmol. 2009;54(5):545–68.PubMedCrossRefGoogle Scholar
  50. 50.
    Finger PT, Tena LB, Semenova E, Aridgides P, Choi WH. Extrascleral extension of choroidal melanoma: post-enucleation high-dose-rate interstitial brachytherapy of the orbit. Brachytherapy. 2014;13(3):275–80.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2020

Authors and Affiliations

  1. 1.Centre for Sight Eye InstituteNew DelhiIndia
  2. 2.The New York Eye Cancer CenterNew YorkUSA

Personalised recommendations